Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INC Research Holdings Inc (INCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: INCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 17.91% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.22M USD | Price to earnings Ratio - | 1Y Target Price 33.56 |
Price to earnings Ratio - | 1Y Target Price 33.56 | ||
Volume (30-day avg) - | Beta 0.58 | 52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 |
52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.39% | Operating Margin (TTM) -86.82% |
Management Effectiveness
Return on Assets (TTM) -7.09% | Return on Equity (TTM) -17.03% |
Valuation
Trailing PE - | Forward PE 6.94 | Enterprise Value 120187421 | Price to Sales(TTM) 0.34 |
Enterprise Value 120187421 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 5.29 | Shares Outstanding 54512600 | Shares Floating 27296363 |
Shares Outstanding 54512600 | Shares Floating 27296363 | ||
Percent Insiders 30.2 | Percent Institutions 5.38 |
Upturn AI SWOT
INC Research Holdings Inc
Company Overview
History and Background
INC Research Holdings Inc., now known as Syneos Health (SYNH), was founded in 1998. It evolved into a global contract research organization (CRO), providing biopharmaceutical companies with clinical development and commercialization services. In 2017, INC Research merged with inVentiv Health to form Syneos Health.
Core Business Areas
- Clinical Development Services: Manages and executes clinical trials for biopharmaceutical companies, including Phase I-IV studies, data management, and regulatory affairs.
- Commercialization Services: Provides commercial solutions, including medical affairs, marketing, and sales services to support product launches and market access.
Leadership and Structure
Prior to the merger, INC Research had a board of directors and an executive leadership team responsible for overseeing the company's operations and strategic direction. Now the company is Syneos Health (SYNH) with Alistair Macdonald as the CEO.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Comprehensive management of clinical trials from protocol design to final report. Market share within the CRO industry is difficult to pinpoint precisely. Competitors include IQVIA (IQV), Laboratory Corporation of America Holdings (LH), and PPD (Thermo Fisher Scientific (TMO)).
- Data Management and Analytics: Provides data management, statistical analysis, and reporting services for clinical trials. Competitors include IQVIA (IQV) and Accenture (ACN).
Market Dynamics
Industry Overview
The CRO industry is experiencing growth driven by increased outsourcing of clinical research by biopharmaceutical companies. Technological advancements, regulatory changes, and globalization are shaping the landscape.
Positioning
INC Research (now Syneos Health) was positioned as a leading mid-sized CRO, offering a full range of services and focusing on therapeutic expertise. It competed with larger CROs like IQVIA.
Total Addressable Market (TAM)
The global CRO market is expected to reach hundreds of billions of USD. INC Research was positioned to capture a portion of this TAM through its service offerings and expertise.
Upturn SWOT Analysis
Strengths
- Strong therapeutic expertise
- Full-service CRO capabilities
- Global presence
- Experienced management team
Weaknesses
- Smaller scale compared to larger CROs like IQVIA
- Reliance on key client relationships
- Potential for project delays or failures
- Competitive pricing pressures
Opportunities
- Increasing demand for outsourced clinical research
- Expansion into new therapeutic areas
- Strategic acquisitions and partnerships
- Adoption of new technologies and data analytics
Threats
- Competition from larger CROs
- Regulatory changes impacting clinical trials
- Economic downturn affecting biopharmaceutical spending
- Loss of key personnel
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
- ICON
Competitive Landscape
INC Research, before the merger, had strengths in specific therapeutic areas and a focus on customer service. Larger competitors had greater scale and broader service offerings. Syneos Health now operates in a highly competitive market.
Major Acquisitions
inVentiv Health
- Year: 2017
- Acquisition Price (USD millions):
- Strategic Rationale: The merger created a leading end-to-end biopharmaceutical solutions organization, combining clinical development and commercialization capabilities.
Growth Trajectory and Initiatives
Historical Growth: INC Research experienced growth through organic expansion and acquisitions prior to the merger.
Future Projections: Future projections are now reflected in Syneos Health (SYNH) performance.
Recent Initiatives: Recent initiatives would be related to Syneos Health integration and strategic priorities.
Summary
INC Research, now Syneos Health, was a mid-sized CRO that focused on clinical development and commercialization services for biopharmaceutical companies. Its merger with inVentiv Health created a larger entity with broader capabilities. Syneos Health operates in a competitive industry and faces challenges related to competition and economic factors. Its ability to integrate operations and capitalize on growth opportunities will determine its future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INC Research Holdings Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-11-07 | CEO & Chairman Mr. Alexander Rabinovich | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 320 | Website https://www.intercure.co |
Full time employees 320 | Website https://www.intercure.co | ||
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.